PI Update for Pradaxa® (dabigatran etexilate) | BI US
Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.
Search
How Much Do You Know About PPID? | Boehringer Ingelheim US
Click here to find out more about some of the common misconceptions you might have about pituitary pars intermedia dysfunction (PPID).
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
Phase III EMPA-KIDNEY trial will stop early
The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.
Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire
Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire
Jardiance® (empagliflozin) Shows Reduction in CV Risk & Death | Boehringer Ingelheim US
BI & Eli Lilly & Co.’s JARDIANCE reduced risk of CV death, non-fatal heart attack or non-fatal stroke by 14%. View ISI, PI and Med Guide.
Ensuring Global Access to Corona Care | Boehringer Ingelheim US
BI has signed a communiqué with the Bill & Melinda Gates Foundation and 15 other companies committing to provide access to COVID-19 related services.
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Your Milestones Drive Ours
Learn more about the experiences of living with nonsmall cell lung cancer and cholangiocarcinoma as well as caring for a loved one during a cancer journey.
Low-WAC interchangeable biosimilar is now available
Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.
esis_employee_acknowledgment_of_mpn.pdf
0055.06_paid_time_off_policy-bipi.pdf
Evolution of prescription digital therapeutics
Ofev-LongForm.pdf
The Globalization of Crime | PDF
Paid time off Policy BIPI
Ofev 4
Ofev 6
Ofev 2
Ofev 5
Daniel Kiesenhofer
Daniel Kiesenhofer talks about his role as Project Manager Quality Control at Boehringer Ingelheim in Vienna, Austria.
Understand the burden of serious mental illness
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
A legacy in the making: Working together to spark meaningful change
Discover Jim’s passion for being an advocate for meaningful causes.